Send to

Choose Destination
J Am Coll Cardiol. 2017 Jan 31;69(4):381-391. doi: 10.1016/j.jacc.2016.10.068. Epub 2016 Dec 28.

Transcatheter Mitral Valve Replacement for Patients With Symptomatic Mitral Regurgitation: A Global Feasibility Trial.

Author information

Departments of Cardiology and Cardiothoracic Surgery, St. Vincent's Hospital, Sydney, Australia. Electronic address:
Center for Valve and Structural Heart Disease and Cardiothoracic Surgery Service, Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, Minnesota.
Departments of Cardiology and Cardiothoracic Surgery, St. Vincent's Hospital, Sydney, Australia.
Departments of Cardiology and Cardiothoracic Surgery, Prince Charles Hospital, Brisbane, Australia.
Divisions of Cardiology and Cardiothoracic Surgery, Baylor University Medical Center, Dallas, Texas.
Departments of Cardiology and Cardiothoracic Surgery, Oslo University Hospital, Oslo, Norway.
Divisions of Cardiology and Cardiothoracic Surgery, Evanston Hospital, Evanston, Illinois.
Departments of Cardiovascular Medicine and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, Ohio.
Division of Cardiology and Department of Cardiothoracic Surgery, Medstar Washington Hospital Center, Washington DC.
Beth Israel Deaconness Medical Center, Boston, Massachusetts.
St. Paul's Hospital, Vancouver, British Columbia, Canada.

Erratum in



Symptomatic mitral regurgitation (MR) is associated with high morbidity and mortality that can be ameliorated by surgical valve repair or replacement. Despite this, many patients with MR do not undergo surgery. Transcatheter mitral valve replacement (TMVR) may be an option for selected patients with severe MR.


This study aimed to examine the effectiveness and safety of TMVR in a cohort of patients with native valve MR who were at high risk for cardiac surgery.


Patients underwent transcatheter, transapical delivery of a self-expanding mitral valve prosthesis and were examined in a prospective registry for short-term and 30-day outcomes.


Thirty patients (age 75.6 ± 9.2 years; 25 men) with grade 3 or 4 MR underwent TMVR. The MR etiology was secondary (n = 23), primary (n = 3), or mixed pathology (n = 4). The Society of Thoracic Surgeons Predicted Risk of Mortality was 7.3 ± 5.7%. Successful device implantation was achieved in 28 patients (93.3%). There were no acute deaths, strokes, or myocardial infarctions. One patient died 13 days after TMVR from hospital-acquired pneumonia. Prosthetic leaflet thrombosis was detected in 1 patient at follow-up and resolved after increased oral anticoagulation with warfarin. At 30 days, transthoracic echocardiography showed mild (1+) central MR in 1 patient, and no residual MR in the remaining 26 patients with valves in situ. The left ventricular end-diastolic volume index decreased (90.1 ± 28.2 ml/m2 at baseline vs. 72.1 ± 19.3 ml/m2 at follow-up; p = 0.0012), as did the left ventricular end-systolic volume index (48.4 ± 19.7 ml/m2 vs. 43.1 ± 16.2 ml/m2; p = 0.18). Seventy-five percent of the patients reported mild or no symptoms at follow-up (New York Heart Association functional class I or II). Successful device implantation free of cardiovascular mortality, stroke, and device malfunction at 30 days was 86.6%.


TMVR is an effective and safe therapy for selected patients with symptomatic native MR. Further evaluation of TMVR using prostheses specifically designed for the mitral valve is warranted. This intervention may help address an unmet need in patients at high risk for surgery. (Early Feasibility Study of the Tendyne Mitral Valve System [Global Feasibility Study]; NCT02321514).


heart failure; mitral prosthesis; mitral regurgitation; mitral valve implantation; transcatheter

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center